BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Binimetinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Binimetinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT01991379-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Binimetinib: Phase 1/2 readout est. (NCT01991379)
DESCRIPTION:Binimetinib\, phase 1/2.\nStudy: MEK162 in Combination With Ima
 tinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stroma
 l Tumor (GIST)\nEstimated primary completion: November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/binimetinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT01991379
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03839342-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Binimetinib: Phase 2 readout est. (NCT03839342)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Binimetinib and Encorafenib for 
 the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03839342
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Binimetinib: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Binimetinib\, phase 3.\nStudy: Identification and Treatment Of 
 Micrometastatic Disease in Stage III Colon Cancer\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /binimetinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03803553
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03947385-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Binimetinib: Phase 1/2 readout est. (NCT03947385)
DESCRIPTION:Binimetinib\, phase 1/2\, Melanoma.\nStudy: Study of IDE196 in 
 Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions\nEs
 timated primary completion: 29 January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03947385
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03971409-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Binimetinib: Phase 2 readout est. (NCT03971409)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Avelumab With Binimetinib\, Saci
 tuzumab Govitecan\, or Liposomal Doxorubicin in Treating Stage IV or Unres
 ectable\, Recurrent Triple Negative Breast Cancer\nEstimated primary compl
 etion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/binimetinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03971409
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05026983-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Binimetinib: Phase 2 readout est. (NCT05026983)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Binimetinib and Encor
 afenib for the Treatment of Metastatic Melanoma and Central Nervous System
  Metastases\nEstimated primary completion: 2 February 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/binimetinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05026983
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05111561-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Binimetinib: Phase 1 readout est. (NCT05111561)
DESCRIPTION:Binimetinib\, phase 1.\nStudy: Testing the Combination of the A
 nticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metast
 atic or Unresectable Solid Tumors With RAS Alterations and Triple Negative
  Breast Cancer\nEstimated primary completion: 14 March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/binimetinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05111561
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05270044-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05270044)
DESCRIPTION:Binimetinib\, phase 3\, Melanoma.\nStudy: Adjuvant Encorafenib 
 and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05270044
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04741997-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Binimetinib: Phase 1 readout est. (NCT04741997)
DESCRIPTION:Binimetinib\, phase 1\, Melanoma.\nStudy: Adjuvant Therapy Base
 d on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Mela
 noma\nEstimated primary completion: April 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04741997
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05286788-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Binimetinib: Phase 2 readout est. (NCT05286788)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: MEKTOVI® for the Treatment of P
 ediatric Adamantinomatous Craniopharyngioma\nEstimated primary completion:
  10 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/binim
 etinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05286788
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04598009-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Binimetinib: Phase 2 readout est. (NCT04598009)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Binimetinib and Imati
 nib for Unresectable Stage III-IV KIT-Mutant Melanoma\nEstimated primary c
 ompletion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/binimetinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04598009
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Binimetinib: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Binimetinib\, phase 3.\nStudy: Personalized Medicine for Advanc
 ed Biliary Cancer Patients\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/binimetinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Binimetinib: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: A Study to Compare th
 e Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimuma
 b + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05355701-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Binimetinib: Phase 1 readout est. (NCT05355701)
DESCRIPTION:Binimetinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Learn About the Study Medicine Called PF-07799933 in People With A
 dvanced Solid Tumors With BRAF Alterations.\nEstimated primary completion:
  31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bini
 metinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05355701
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Binimetinib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Nivolumab With Tramet
 inib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients 
 With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstima
 ted primary completion: 8 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04061980-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Binimetinib: Phase 2 readout est. (NCT04061980)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Encorafenib and Binimetinib With
  or Without Nivolumab in Treating Patients With Metastatic Radioiodine Ref
 ractory BRAF V600 Mutant Thyroid Cancer\nEstimated primary completion: 30 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/binime
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04061980
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Binimetinib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Dire
 cted by Genetic Testing in Treating Patients With Advanced Refractory Soli
 d Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06887088-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Binimetinib: Phase 2 readout est. (NCT06887088)
DESCRIPTION:Binimetinib\, phase 2\, Melanoma.\nStudy: Encorafenib and biNim
 etinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant m
 elanOma and Symptomatic Brain Metastases\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/binimetin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6887088
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06159478-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Binimetinib: Phase 2 readout est. (NCT06159478)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Binimetinib in Patients With BRA
 F Fusion-positive Low-grade Glioma or Pancreatic Cancer\nEstimated primary
  completion: 28 February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/binimetinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06159478
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322383-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Binimetinib: Phase 2 readout est. (NCT04322383)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Binimetinib for People With Rela
 psed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant\nEstimated 
 primary completion: 30 April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04322383
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04903119-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Binimetinib: Phase 1 readout est. (NCT04903119)
DESCRIPTION:Binimetinib\, phase 1\, Melanoma.\nStudy: Nilotinib Plus Dabraf
 enib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma\nEstimat
 ed primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/binimetinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04903119
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05554367-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20280826
DTEND;VALUE=DATE:20280827
SUMMARY:Binimetinib: Phase 2 readout est. (NCT05554367)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Palbociclib and Binimetinib in R
 AS-Mutant Cancers\, A ComboMATCH Treatment Trial\nEstimated primary comple
 tion: 26 August 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /binimetinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05554367
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04913285-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Binimetinib: Phase 1 readout est. (NCT04913285)
DESCRIPTION:Binimetinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation P
 ositive Solid Tumors\nEstimated primary completion: 30 November 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/binimetinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04913285
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06207656-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Binimetinib: Phase 2 readout est. (NCT06207656)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Study to Evaluate the Efficacy a
 nd Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As
  Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Pot
 entially Resectable Advanced Colorectal Cancer\nEstimated primary completi
 on: 1 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bin
 imetinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06207656
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Binimetinib: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Binimetinib\, phase 4.\nStudy: The FLOTILLA Study: Providing Co
 ntinued Access to The Study Medicines Encorafenib and Binimetinib for Part
 icipants in Prior Clinical Trials\nEstimated primary completion: 31 July 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/binimetinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05203172
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564377-1996@assetmemo.bio
DTSTAMP:20261121T004058Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Binimetinib: Phase 2 readout est. (NCT05564377)
DESCRIPTION:Binimetinib\, phase 2.\nStudy: Targeted Therapy Directed by Gen
 etic Testing in Treating Patients With Locally Advanced or Advanced Solid 
 Tumors\, The ComboMATCH Screening Trial\nEstimated primary completion: 1 J
 uly 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/binimetinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT055
 64377
URL:https://assetmemo.bio/drug/binimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
